<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011430</article-id><article-id pub-id-type="publisher-id">ACM-38953</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_80096204.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于生物信息学鉴定和分析SNP突变基因在胃癌中的预后和应用价值
  Identification and Validation of SNP-Containing Genes with Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晖</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>昊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>英骥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>志威</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>功竣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>卫卫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>文生</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2832</fpage><lpage>2847</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    背景：胃癌是全球最常见的恶性肿瘤之一。尽管近年来对该疾病的诊断和治疗已有实质性改善，但由于局部复发和远处转移，胃癌的五年生存率仍然较低。对胃癌分子发病机理及相关预后标志物的深入研究将有助于改善胃癌患者的生活质量和预后。这项研究的目的是鉴定和验证具有胃癌预后价值的SNP突变基因并探索其在胃癌中的应用价值。方法：从癌症基因组图谱(TCGA)数据库中获得胃癌患者的SNP相关数据，并使用DAVID软件分析突变基因的功能和下游通路。使用STRING数据库构建蛋白质–蛋白质相互作用(PPI)网络，并通过Cytoscape软件可视化。分子复合物检测(MCODE)用以筛选PPI网络以提取重要的突变基因，使用cytoHubba鉴定了10个中枢基因，并通过UALCAN和Kaplan-Meier Plotter网站确定了中枢基因的表达水平和预后。最后，定量PCR和蛋白质印迹实验被用来验证中枢基因在胃癌细胞中的表达。结果：从数据库中鉴定出超过25个样本中的945个SNP突变基因。PPI网络具有360个节点和1616个边缘。最后，cytoHubba鉴定了六个关键基因(TP53，HRAS，BRCA1，PIK3CA，AKT1和SMARCA4)，它们的表达水平与胃癌患者的生存率密切相关。结论：我们的结果表明，SNP突变相关基因TP53，HRAS，BRCA1，PIK3CA，AKT1和SMARCA4可能是胃癌发展和预后的关键基因。本研究为进一步探索胃癌的分子发病机制和评估患者预后提供了重要的生物信息学基础和相关的理论基础。
    Gastric cancer is one of the most common malignancies worldwide. An in-depth study of the molecular pathogenesis of gastric cancer and related prognostic markers will help improve the quality of life and prognosis of patients with this disease. The purpose of this study was to identify and verify key SNPs in genes with prognostic value for gastric cancer. SNP-related data from gastric cancer patients were obtained from The Cancer Genome Atlas (TCGA) database, and the functions and pathways of the mutated genes were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software. A protein-protein interaction (PPI) network was constructed using the STRING database and visualized by Cytoscape software, and molecular complex detection (MCODE) was used to screen the PPI network to extract important mutated genes. Ten hub genes were identified using cytoHubba, and the expression levels and the prognostic value of the central genes were determined by UALCAN and Kaplan-Meier Plotter. Finally, quantitative PCR was used to verify the expression of the hub genes in gastric cancer cells. From the database, 945 genes with mutations in more than 25 samples were identified. CytoHubba identified six key SNP-containing genes (TP53, HRAS, BRCA1, PIK3CA, AKT1, and SMARCA4), and their expression levels were closely related to the survival rate of gastric cancer patients. Our research provides an important bioinformatics foundation and related theoretical foundation for further exploring the molecular pathogenesis of gastric cancer and evaluating the prognosis of patients. Further investigations of SNP-containing genes in gastric cancer may contribute to therapeutic advances. 
  
 
</p></abstract><kwd-group><kwd>胃癌，单核苷酸多态性，生物标志物，预后，生物信息学分析, Gastric Cancer</kwd><kwd> Single Nucleotide Polymorphisms</kwd><kwd> Biomarkers</kwd><kwd> Prognosis</kwd><kwd> Bioinformatics Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>背景：胃癌是全球最常见的恶性肿瘤之一。尽管近年来对该疾病的诊断和治疗已有实质性改善，但由于局部复发和远处转移，胃癌的五年生存率仍然较低。对胃癌分子发病机理及相关预后标志物的深入研究将有助于改善胃癌患者的生活质量和预后。这项研究的目的是鉴定和验证具有胃癌预后价值的SNP突变基因并探索其在胃癌中的应用价值。方法：从癌症基因组图谱(TCGA)数据库中获得胃癌患者的SNP相关数据，并使用DAVID软件分析突变基因的功能和下游通路。使用STRING数据库构建蛋白质–蛋白质相互作用(PPI)网络，并通过Cytoscape软件可视化。分子复合物检测(MCODE)用以筛选PPI网络以提取重要的突变基因，使用cytoHubba鉴定了10个中枢基因，并通过UALCAN和Kaplan-Meier Plotter网站确定了中枢基因的表达水平和预后。最后，定量PCR和蛋白质印迹实验被用来验证中枢基因在胃癌细胞中的表达。结果：从数据库中鉴定出超过25个样本中的945个SNP突变基因。PPI网络具有360个节点和1616个边缘。最后，cytoHubba鉴定了六个关键基因(TP53，HRAS，BRCA1，PIK3CA，AKT1和SMARCA4)，它们的表达水平与胃癌患者的生存率密切相关。结论：我们的结果表明，SNP突变相关基因TP53，HRAS，BRCA1，PIK3CA，AKT1和SMARCA4可能是胃癌发展和预后的关键基因。本研究为进一步探索胃癌的分子发病机制和评估患者预后提供了重要的生物信息学基础和相关的理论基础。</p></sec><sec id="s2"><title>关键词</title><p>胃癌，单核苷酸多态性，生物标志物，预后，生物信息学分析</p></sec><sec id="s3"><title>Identification and Validation of SNP-Containing Genes with Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis<sup> </sup></title><p>Hui Li<sup>*</sup>, Hao Wu<sup>*</sup>, Yingji Ma, Zhiwei Liang, Gongjun Wang, Weiwei Qi<sup>#</sup>, Wensheng Qiu<sup>#</sup></p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/64-1571637x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 23<sup>rd</sup>, 2020; published: Nov. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/64-1571637x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Gastric cancer is one of the most common malignancies worldwide. An in-depth study of the molecular pathogenesis of gastric cancer and related prognostic markers will help improve the quality of life and prognosis of patients with this disease. The purpose of this study was to identify and verify key SNPs in genes with prognostic value for gastric cancer. SNP-related data from gastric cancer patients were obtained from The Cancer Genome Atlas (TCGA) database, and the functions and pathways of the mutated genes were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software. A protein-protein interaction (PPI) network was constructed using the STRING database and visualized by Cytoscape software, and molecular complex detection (MCODE) was used to screen the PPI network to extract important mutated genes. Ten hub genes were identified using cytoHubba, and the expression levels and the prognostic value of the central genes were determined by UALCAN and Kaplan-Meier Plotter. Finally, quantitative PCR was used to verify the expression of the hub genes in gastric cancer cells. From the database, 945 genes with mutations in more than 25 samples were identified. CytoHubba identified six key SNP-containing genes (TP53, HRAS, BRCA1, PIK3CA, AKT1, and SMARCA4), and their expression levels were closely related to the survival rate of gastric cancer patients. Our research provides an important bioinformatics foundation and related theoretical foundation for further exploring the molecular pathogenesis of gastric cancer and evaluating the prognosis of patients. Further investigations of SNP-containing genes in gastric cancer may contribute to therapeutic advances.</p><p>Keywords:Gastric Cancer, Single Nucleotide Polymorphisms, Biomarkers, Prognosis, Bioinformatics Analysis</p><disp-formula id="hanspub.38953-formula51"><graphic xlink:href="//html.hanspub.org/file/64-1571637x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/64-1571637x8_hanspub.png" /> <img src="//html.hanspub.org/file/64-1571637x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 介绍</title><p>胃癌是全球第五大最常见的恶性肿瘤，也是癌症相关死亡的第二大主要原因 [<xref ref-type="bibr" rid="hanspub.38953-ref1">1</xref>]。尽管近年来胃癌的治疗策略已得到实质性改善，但由于各种遗传突变和导致该病发展的异常信号通路，胃癌的死亡率仍然很高 [<xref ref-type="bibr" rid="hanspub.38953-ref2">2</xref>]。作为一种复杂的疾病，其发生和发展涉及一系列遗传，表观遗传和表型变化。涉及多种生物学途径的基因多态性已被确定为胃癌的潜在危险因素 [<xref ref-type="bibr" rid="hanspub.38953-ref3">3</xref>]。鉴于胃癌的高发病率和死亡率，确定其潜在的分子机制和遗传特征以及阐明用于诊断和预后的生物学指标对于胃癌患者的个性化和精确治疗至关重要。</p><p>基于高通量测序的生物信息学分析是探索肿瘤发病机理的分子机制、鉴定可用于早期诊断的生物标志物以及发现治疗靶标的重要方法。单核苷酸多态性(SNP)是生物体基因组中常见的核苷酸多态性。在不同物种的个体中，基因组DNA序列相同位置的单个核苷酸会发生取代，插入或缺失以及其他突变，从而导致该位点的单个核苷酸发生变化 [<xref ref-type="bibr" rid="hanspub.38953-ref4">4</xref>]。SNP通常被认为是导致个体易感性差异的遗传基础和潜在的癌症标志物。包含SNP的基因的分析对于癌症的早期诊断和个性化靶向治疗很重要。</p><p>癌症基因组图谱(TCGA)数据库可用于高通量基因组分析。为了进一步探讨含SNP的基因在胃癌的诊断和预后中的生物学意义，我们从TCGA数据库下载了胃癌相关的SNP数据，并使用了生物信息学分析方法，包括突变分析，功能和途径富集分析，蛋白质–蛋白质相互作用(PPI)网络分析等。我们的目的是探索与胃癌的诊断和预后密切相关的SNP突变基因，并为胃癌的个体化和精准治疗提供科学的理论基础。</p></sec><sec id="s6"><title>2. 材料和方法</title><sec id="s6_1"><title>2.1. 数据处理与分析</title><p>TCGA数据均已转移到新建立的基因组数据共享平台(https://gdc.cancer.gov/) [<xref ref-type="bibr" rid="hanspub.38953-ref5">5</xref>]。由于TCGA中有关SNP的原始数据尚未公开，因此我们下载了已处理的胃癌SNP相关数据和原始mRNA表达数据。从413个样本(包括32个正常样本和381个癌症样本)中收集了mRNA数据。突变的基因是从下载的胃癌样品的SNP数据中获得的。使用edgeR软件包对下载的mRNA原始数据进行整合和标准化，并进行分析以获得差异表达的基因及其表达水平。TCGA提供的mRNA数据是公开可用的。</p></sec><sec id="s6_2"><title>2.2. 突变基因的功能富集和途径分析</title><p>为了阐明由这些突变基因引起的功能障碍，我们使用了DAVID (http://www.DAVID.org) [<xref ref-type="bibr" rid="hanspub.38953-ref6">6</xref>] 数据库来进行基因本体论(GO)以及京都基因与基因组百科全书(KEGG)上的基因分析。作为开放源代码平台，DAVID可用于确定目标分子之间的缔合。通过选择GO项和KEGG途径，并使用P &lt; 0.05作为临界值，我们鉴定了突变基因的分子功能(Molecular Function)，生物过程(Biological Process)，细胞成分(Cellular Components)和所涉及的下游通路。</p></sec><sec id="s6_3"><title>2.3. 突变基因PPI网络的构建和基因表达分析</title><p>在这项研究中，使用STRING数据库 [<xref ref-type="bibr" rid="hanspub.38953-ref7">7</xref>] 对选定的包含SNP的基因进行PPI网络分析，然后使用Cytoscape可视化，以置信度得分 &gt; 0.4作为截止标准 [<xref ref-type="bibr" rid="hanspub.38953-ref8">8</xref>]。Cytoscape插件cytoHubba [<xref ref-type="bibr" rid="hanspub.38953-ref9">9</xref>] 用于通过从12种拓扑分析方法中找到前30个基因的交点，然后使用分子复合物检测(MCODE)来建立PPI网络的模块，进而识别中枢基因。</p></sec><sec id="s6_4"><title>2.4. 突变基因的Kaplan-Meier生存曲线和预后生物标志物的筛选</title><p>Kaplan-Meier Plotter (https://kmplot.com/analysis/)可以使用基因表达数据评估乳腺癌，肺癌，胃癌和卵巢癌患者的生存率 [<xref ref-type="bibr" rid="hanspub.38953-ref10">10</xref>]。无复发生存期(RFS)和总生存期(OS)数据可从GEO (仅Affymetrix微阵列)、EGA和TCGA下载。该工具的主要目的是基于荟萃分析的生物标志物评估 [<xref ref-type="bibr" rid="hanspub.38953-ref11">11</xref>]。使用Kaplan-Meier图表，我们评估了SNP突变基因对胃癌患者预后的影响，并最终确定了可用作该疾病预后生物标志物的关键基因。</p></sec><sec id="s6_5"><title>2.5. 通过UALCAN验证中枢基因</title><p>UALCAN (http://ualcan.path.uab.edu/)可以基于3级RNA序列和TCGA数据库中31种癌症类型的临床数据进行标准化分析 [<xref ref-type="bibr" rid="hanspub.38953-ref12">12</xref>]。在这项研究中，使用UALCAN数据库来验证中枢基因在正常和癌症样本之间的表达。我们选择P &lt; 0.05，倍数变化 &gt; 2作为阈值。</p></sec><sec id="s6_6"><title>2.6. 通过cBioPortal分析癌症基因组学数据</title><p>cBioPortal for Cancer Genomics (http://cbioportal.org)提供了可视化和分析多维癌症基因组学数据的资源 [<xref ref-type="bibr" rid="hanspub.38953-ref13">13</xref>]。在这项研究中，基于四种选定的胃癌亚型的突变和DNA拷贝数的变化，我们对关键基因的基因组变化进行了分析。</p></sec><sec id="s6_7"><title>2.7. 细胞培养和抗体</title><p>AGS，HGC27和GES-1细胞系购自中国科学院细胞研究所，并在含有10%胎牛血清(FBS)的RPMI- 1640培养基中培养。FBS和RPMI-1640购自Gibco (美国纽约)。将细胞置于37℃的培养箱中，CO<sub>2</sub>浓度为5%。TP53 (#2527)，BRCA1 (#14823)，PIK3CA (#4255)，AKT1 (#2938)和SMARCA4 (#49360)的抗体购自Cell Signaling Technology (美国马萨诸塞州贝弗利)。针对HRAS的抗体(abs137096)和β肌动蛋白抗体(abs132001)获自Absin (中国上海)。本研究中使用的二抗包括山羊抗小鼠IgG-HRP (abs20001)和山羊抗兔IgG-HRP (abs20002)，两者均从Absin获得。</p></sec><sec id="s6_8"><title>2.8. qPCR检测中枢基因的表达水平</title><p>根据制造商的说明，使用TRIzol试剂(TaKaRa，中国北京)从细胞中分离总RNA，并使用PrimeScript RT Master Mix试剂(TaKaRa，中国北京)反转录为cDNA。使用ABI 7500HT快速实时PCR系统(美国加利福尼亚州Applied Biosystems)进行实时定量PCR (qRT-PCR)，然后进行熔解曲线分析。使用以下循环条件：95℃ 5分钟，然后进行40个循环，分别是95℃ 20秒和60℃ 30秒。我们使用2<sup>-ΔΔCt</sup>方法(以GAPDH作为内部对照)来确定mRNA表达的平均相对倍数变化。引物如表1所示。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Upstream and downstream sequences of key gene primer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Primer name</th><th align="center" valign="middle" >Sense</th><th align="center" valign="middle" >Antisense</th></tr></thead><tr><td align="center" valign="middle" >TP53 HRAS BRCA1 PIK3CA AKT1 SMARCA4</td><td align="center" valign="middle" >GAGGTTGGCTCTGACTGTACC GACGTGCCTGTTGGACATC GAAACCGTGCCAAAAGACTTC AGTAGGCAACCGTGAAGAAAAG AGCGACGTGGCTATTGTGAAG GAAACAAGACGACTTTGTGACCT</td><td align="center" valign="middle" >TCCGTCCCAGTAGATTACCAC CTTCACCCGTTTGATCTGCTC CCAAGGTTAGAGAGTTGGACAC GAGGTGAATTGAGGTCCCTAAGA GCCATCATTCTTGAGGAGGAAGT CTTCACGGTTGCCTACTGGT</td></tr></tbody></table></table-wrap><p>表1.关键基因引物的上下游序列</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 数据处理与分析</title><p>使用VarScan方法从TCGA数据库的第二代测序数据中提取胃癌样品的生殖/体细胞突变数据作为SNP数据，选择了945个具有SNP突变的基因。在大于50个样本数中有96个基因发生了突变(图1)。从TCGA数据库中获得了413份具有胃癌基因表达数据的样本，包括32份正常组织样本和381份癌组织样本。使用EdgeR软件包分析胃癌和正常组织样品之间的差异表达(图2)，以|logFC| &gt; 2和P &lt; 0.01为截止标准。我们进一步分析了胃癌中SNP突变基因和差异表达的基因，以探讨由基因突变和异常表达引起的功能障碍。</p><p>图1. 在90多个样本中突变的10个基因的瀑布图</p><p>图2. 差异基因表达的火山图</p></sec><sec id="s7_2"><title>3.2. 突变基因的功能富集和途径分析</title><p>为了进一步阐明突变基因在胃癌中的功能，我们使用了DAVID在线软件对945个突变基因进行了功能富集分析和通路分析。功能富集分析表明，在生物过程类别中，SNP突变基因主要集中在通过质膜粘附分子的同性细胞粘附，动作电位和神经元动作电位的膜去极化。在细胞组分类别中，突变基因主要分类在质膜，蛋白质细胞外基质和电压门控钠通道复合物中。在分子功能类别中，这些基因主要富含钙离子结合，细胞外基质结构成分和电压门控钠通道活性(表2)。通路富集分析揭示了与癌症相关的许多信号传导途径中均含有SNP基因的富集，包括磷脂酰肌醇3激酶(PI3K)/Akt信号传导途径，钙信号传导途径和环状鸟苷单磷酸(cGMP)-PKG信号传导途径(图3)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Gene ontology analysis of 945 mutant genes in gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Category</th><th align="center" valign="middle" >Term</th><th align="center" valign="middle" >Count</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >homophilic cell adhesion via plasma membrane adhesion molecules</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >1.13E−35</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >negative regulation of transcription from RNA polymerase II promoter</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >0.0075481</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >intracellular signal transduction</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >0.0033163</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >cell adhesion</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >2.98E−06</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >membrane depolarization during action potential</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >8.42E−15</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >axon guidance</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >1.11E−05</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >heart development</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >2.29E−04</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >cell migration</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0.0085702</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >neuronal action potential</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.0337519</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >microtubule cytoskeleton organization</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >1.60E−09</td></tr><tr><td align="center" valign="middle" >GOTERM_MF_DIRET</td><td align="center" valign="middle" >GO:0005509~calcium ion binding</td><td align="center" valign="middle" >99</td><td align="center" valign="middle" >3.414E−26</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0005524~ATP binding</td><td align="center" valign="middle" >99</td><td align="center" valign="middle" >1.153E−06</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0008270~zinc ion binding</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >0.0263632</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0003677~DNA binding</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >0.0361054</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0003682~chromatin binding</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >0.0180564</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0044212~transcription regulatory region DNA binding</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >9.495E−06</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0005096~GTPase activator activity</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >0.0093759</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0016887~ATPase activity</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5.068E−05</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0004842~ubiquitin-protein transferase activity</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0.0201426</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >GO:0004725~protein tyrosine phosphatase activity</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >9.479E−09</td></tr><tr><td align="center" valign="middle" >GOTERM_CC_DIRECT</td><td align="center" valign="middle" >integral component of membrane</td><td align="center" valign="middle" >197</td><td align="center" valign="middle" >0.0385191</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >plasma membrane</td><td align="center" valign="middle" >133</td><td align="center" valign="middle" >2.329E−12</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >integral component of plasma membrane</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >0.0021151</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >proteinaceous extracellular matrix</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >6.187E−12</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >cell surface</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >0.0006393</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >focal adhesion</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >0.0002001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >dendrite</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >8.302E−07</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >neuronal cell body</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >6.336E−05</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >voltage-gated potassium channel complex</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >6.437E−07</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >postsynaptic density</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >2.216E−07</td></tr></tbody></table></table-wrap><p>表2. 胃癌中945个基因的生物学功能分析</p><p>图3. 945个突变基因的通路富集图</p></sec><sec id="s7_3"><title>3.3. 构建突变基因的PPI网络</title><p>为了进一步研究突变基因之间的潜在关系，我们使用了STRING在线数据库来挖掘这些基因之间的相互作用。Cytoscape软件用于可视化复杂的PPI网络，该网络包括360个节点和1616个边缘(图4(a))。 MCODE用于从PPI网络获取重要模块，包括25个节点和245个边缘(图4(b))。功能和KEGG通路富集分析表明，重要模块的生物过程类别主要包括生物调节和细胞通讯。细胞组分类别包括细胞核，膜封闭腔和蛋白质复合物；分子功能类别主要包括蛋白质结合，离子结合和转移酶活性(图4(c))。KEGG通路富集分析表明，重要的模块基因主要富集在FoxO信号通路和甲状腺激素信号通路中(图5)。</p></sec><sec id="s7_4"><title>3.4. 关键基因的筛选和生存分析</title><p>使用cytoHubba的12种算法中前30个基因的交集，我们确定了10个中枢基因：TP53，EP300，AKT1，HRAS，PTEN，PIK3CA，SMARCA4，CREBBP，BRCA1和ATM (图6(A))。使用Metascape工具来分析关键基因的通路和生物过程富集。我们观察到中枢基因主要富集在PID-P53下游，细胞凋亡，调节细胞对应激的反应等通路中(图6(B)，图6(C))。cBioPortal在线平台提供了中枢基因遗传变异的图形分析。如图所示，在胃癌中，有10个关键SNP基因均显示出高突变率，基因组变化率在8%至45%之间(图6(D))。为了确定所选的中枢基因是否具有临床相关性，我们使用Kaplan-Meier曲线分析了这些基因的单变量存活率，发现TP53，HRAS，BRCA1，PIK3CA，AKT1和SMARCA4的表达与预后相关(图7)。因此，这些关键基因可作为胃癌的预后指标。</p></sec><sec id="s7_5"><title>3.5. 通过UALCAN验证集线器基因</title><p>UALCAN是一种在线工具，具有TCGA和GTEx的数据，用于验证这些关键基因在胃癌中的表达。在这项研究中，根据来自TCGA数据库的RNA序列数据，比较了胃肿瘤样品和邻近的正常组织中6个基因(TP53，HRAS，BRCA1，PIK3CA，AKT1，SMARCA4)的mRNA表达水平。发现这六个基因在415个胃癌组织中与34个正常组织相比在转录水平上高表达(图8)。我们选择P &lt; 0.05，倍数变化 &gt; 2作为阈值。</p><p>图4. 突变基因的PPI网络的构建和重要模块的分析</p><p>图5. 重要模块的通路富集图</p><p>图6. 关键基因的选择和分析</p><p>图7. 使用Kaplan-Meier曲线对关键基因进行单变量生存分析</p><p>图8. 关键SNP突变基因表达的分析</p></sec><sec id="s7_6"><title>3.6. 预后相关基因的基因组变化</title><p>我们使用cBioPortal工具从TCGA数据库中选择了478个样品，并研究了六个预后相关基因的基因组特异性变化。对癌症类型的汇总分析显示，在TCGA的胃癌数据集(包括粘液性胃腺癌，弥漫型胃腺癌，胃腺癌，和肾小管腺癌)中，这6个基因的基因组改变频率范围为12.66%至51.90% (图9)。</p><p>图9. 5个胃癌数据集中关键基因的基因组特异性变化</p></sec><sec id="s7_7"><title>3.7. 胃癌中六个基因的基因表达水平</title><p>使用qRT-PCR分析胃癌中TP53，HRAS，BRCA1，PIK3CA，AKT1，SMRACA4的表达。结果表明，与胃正常细胞GES-1相比，6个基因在胃癌细胞AGS和HGC27中的表达上调(图10)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>胃癌是一种复杂的疾病，是全球第五大最常见的恶性肿瘤，也是与癌症相关的第二大死亡原因 [<xref ref-type="bibr" rid="hanspub.38953-ref14">14</xref>]。为了提高患者的生活质量和预后并延长其生存时间，研究人员必须进一步阐明导致胃癌恶性生物学行为的分子机制。根据以前的报道，遗传多态性将增加患癌症的风险，被认为是各种癌症预后不良的指标和潜在的致癌标志物。因此，对SNP突变基因的鉴定分析可为治疗胃癌患者的个体化精准治疗和预测临床预后提供新思路。</p><p>图10. 关键基因在胃癌细胞中的表达</p><p>在这项研究中，我们对TCGA数据库中与胃癌相关的数据进行了一系列生物信息学分析，以筛选和鉴定与SNP相关的预后生物标志物。我们对这些基因进行了功能和通路富集分析，发现这些基因在细胞核和蛋白质复合物中富集，主要调节多细胞生物学过程，发育过程和代谢过程。通路分析表明，胃癌中SNP突变基因主要参与PI3K-AKT通路，CGMP-PKG通路，钙信号通路和许多其他与癌症相关的通路。功能和通路富集分析揭示SNP基因在癌症发展中的分子机制。</p><p>我们筛选了与胃癌的发生和发展密切相关的六个突变基因，TP53，AKT1，HRAS，PTEN，PIK3CA，SMARCA4，BRCA1。生存分析表明这六个基因的高表达与胃癌预后不良有关。使用UALCAN在线分析，我们发现这6个基因在胃癌组织中的表达明显高于正常组织。随后的细胞实验证实了这一结果。此外，我们还使用了cBioPortal工具从TCGA数据库中研究了胃癌患者6个关键基因的基因组变化。我们发现这些基因在管状胃腺癌中的突变频率最高。六个基因的基因组改变率在12.66%至51.90%之间。</p><p>TP53 (肿瘤蛋白p53)是胃癌中突变频率最高的基因(约50%)，也是人类癌症中最常见的突变基因。该基因在细胞周期停滞，细胞衰老，凋亡，分化和代谢中起重要作用 [<xref ref-type="bibr" rid="hanspub.38953-ref15">15</xref>]。作为肿瘤分子生物学领域的研究热点，该基因的突变与各种癌症的预后不良有关 [<xref ref-type="bibr" rid="hanspub.38953-ref16">16</xref>]。多数TP53突变是错义突变和由单个核苷酸取代引起的基因缺失，从而导致TP53活性发生变化。p53突变蛋白不仅失去野生型p53蛋白的抗肿瘤作用，而且还增强了肿瘤细胞的活性，促进侵袭和转移以及肿瘤的发生发展 [<xref ref-type="bibr" rid="hanspub.38953-ref17">17</xref>]。先前的研究已证明TP53与胃癌之间的关系 [<xref ref-type="bibr" rid="hanspub.38953-ref18">18</xref>]。Ando等人研究了182例胃癌的临床样本，发现TP53阳性肿瘤比其他肿瘤具有更深的侵袭和更多的淋巴结转移和肝转移，并且某些基因(PICT1，RPL11)参与了通过TP53进行的癌症进展 [<xref ref-type="bibr" rid="hanspub.38953-ref19">19</xref>]。TP53突变发生在胃癌发生的晚期，有助于最终转变为癌症 [<xref ref-type="bibr" rid="hanspub.38953-ref20">20</xref>]。另有研究发现TP53突变可抑制胃癌的肿瘤免疫力 [<xref ref-type="bibr" rid="hanspub.38953-ref21">21</xref>]。根据我们的分析结果，TP53基因的突变程度在10个中心基因中最高，其表达增加与胃癌的5年生存率负相关，这进一步证实了这项研究的有效性。TP53突变基因型的进一步探索将有助于揭示胃癌发生和发展的分子机制。</p><p>HRAS是RAS基因家族的成员，其参与RAS蛋白信号转导的激活。RAS蛋白是一种GDP/GTP结合蛋白，主要调节野生型细胞的增殖，分化和衰老 [<xref ref-type="bibr" rid="hanspub.38953-ref22">22</xref>]。HRAS在激活后起癌基因的作用，激活通常通过突变(SNP，插入，易位)和表达增加而发生 [<xref ref-type="bibr" rid="hanspub.38953-ref23">23</xref>]。与HRAS相关的疾病包括乳腺癌，肝癌，甲状腺癌和膀胱癌 [<xref ref-type="bibr" rid="hanspub.38953-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref27">27</xref>]。HRAS的异位表达可促进胃癌细胞的增殖，迁移，侵袭，血管生成和克隆形成 [<xref ref-type="bibr" rid="hanspub.38953-ref28">28</xref>]。我们的结果表明，HRAS在胃癌的诊断和治疗中可能起重要作用。</p><p>乳腺癌敏感性基因(BRCA1)属于一类具有高渗透率的抑癌基因，在对DNA损伤(包括DNA双链断裂)的反应中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.38953-ref29">29</xref>]。BRCA1蛋白可以与各种蛋白结合以调节基因转录，从而保持基因组的完整性。BRCA1基因突变导致DNA复制错误和突变，从而促进异常细胞增殖并导致肿瘤发生 [<xref ref-type="bibr" rid="hanspub.38953-ref30">30</xref>]。越来越多的证据表明，BRCA1与乳腺癌，卵巢癌和结肠癌广泛相关 [<xref ref-type="bibr" rid="hanspub.38953-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref32">32</xref>]。有趣的是，据报道BRCA1在胃癌细胞中的作用是不同的，并且观察到了不同的表达水平。BRCA1在细胞质中的表达下调，BRCA1在细胞核中的表达上调，这与晚期肿瘤的不良预后有关 [<xref ref-type="bibr" rid="hanspub.38953-ref33">33</xref>]。BRCA1基因多态性也与胃癌的易感性有关 [<xref ref-type="bibr" rid="hanspub.38953-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref35">35</xref>]。我们的研究表明，BRCA1在胃癌中的表达高于正常胃组织，且其高表达与预后不良有关，这表明BRCA1在不同类型的肿瘤中可能起相反作用，而BRCA1在胃癌中的作用值得我们进一步探索。</p><p>PI3K-Akt信号转导通路在肿瘤发生，发展，治疗和预后中起着重要作用 [<xref ref-type="bibr" rid="hanspub.38953-ref36">36</xref>]。PI3K是PI3K信号通路的组成部分，在细胞增殖，存活和粘附的调节中起关键作用，并且在人类癌症中常常被上调 [<xref ref-type="bibr" rid="hanspub.38953-ref37">37</xref>]。PIK3CA (磷酸肌醇-3-激酶，催化α基因)编码PI3K的p110α亚基。它在肿瘤细胞的增殖，分化，转运和代谢中起重要作用 [<xref ref-type="bibr" rid="hanspub.38953-ref38">38</xref>]。此外，PIK3CA途径调节血管生成和对癌症的免疫反应 [<xref ref-type="bibr" rid="hanspub.38953-ref39">39</xref>]。在大约30%的人类癌症中发现了PIK3CA突变 [<xref ref-type="bibr" rid="hanspub.38953-ref40">40</xref>]，包括乳腺癌，卵巢癌，结肠癌和前列腺癌 [<xref ref-type="bibr" rid="hanspub.38953-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref43">43</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref44">44</xref>]。在胃癌中，PIK3CA蛋白的高表达与肿瘤的侵袭性，肿瘤的表型和患者的不良生存密切相关 [<xref ref-type="bibr" rid="hanspub.38953-ref45">45</xref>]。PIK3CA突变与T期高，分化差和微卫星不稳定性相关 [<xref ref-type="bibr" rid="hanspub.38953-ref46">46</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref47">47</xref>]。在我们的研究中，相关分析表明，PIK3CA在肿瘤组织中的表达明显高于正常组织。OS分析表明，胃癌预后差与PIK3CA高表达有关，提示PIK3CA可作为胃癌预后的潜在生物标志物。</p><p>AKT是PIK3的直接下游靶蛋白。越来越多的证据表明，AKT蛋白的激活在癌症的发展中起着重要的生物学作用 [<xref ref-type="bibr" rid="hanspub.38953-ref48">48</xref>]。AKT1是AKT的子类型之一。活化的AKT1使许多下游底物磷酸化，并参与细胞生长，代谢，增殖，凋亡和其他过程的调控 [<xref ref-type="bibr" rid="hanspub.38953-ref49">49</xref>]。Petrini等人发现AKT1在胃癌中过表达的患者预后较差，提示AKT1可作为胃癌预后较差的标志物 [<xref ref-type="bibr" rid="hanspub.38953-ref50">50</xref>]。Ghatak等。发现AKT1突变与胃癌的异常细胞周期有关 [<xref ref-type="bibr" rid="hanspub.38953-ref51">51</xref>]。通路分析表明，AKT1涉及PI3K-AKT，MAPK和其他与癌症密切相关的其他途径，这表明编码AKT1的基因在癌症的发展中具有重要的生物学功能。</p><p>ATP依赖的染色质重塑在癌症的发生和发展中起着重要作用，几乎参与了DNA代谢的所有方面，例如转录，重组，DNA修复和DNA复制 [<xref ref-type="bibr" rid="hanspub.38953-ref52">52</xref>]。SWI/SNF复合物(BAF复合物)是染色质重塑的第一个发现机制。SMARCA4编码的蛋白质(也称为BGR1)是SWI/SNF家族的成员，具有解旋酶和ATP酶活性，并通过改变染色质的结构来调节基因转录 [<xref ref-type="bibr" rid="hanspub.38953-ref53">53</xref>]。SMARCA4通常被认为是肿瘤抑制基因 [<xref ref-type="bibr" rid="hanspub.38953-ref54">54</xref>]。但是，最近的一些报道表明，SMARCA4在某些类型的癌症中对细胞存活和增殖起着重要作用 [<xref ref-type="bibr" rid="hanspub.38953-ref55">55</xref>] [<xref ref-type="bibr" rid="hanspub.38953-ref56">56</xref>]。Martinez等发现SMARCA4在包括胃癌组织在内的11种肿瘤组织中高表达，并且与不良预后有关 [<xref ref-type="bibr" rid="hanspub.38953-ref57">57</xref>]，这反映了SMARCA4在癌症中的双重作用。在我们的研究中，SMARCA4在胃癌细胞中的表达高于正常细胞。OS分析表明SMARCA4的高表达与不良预后有关，这与以前的研究一致，并进一步证实了我们的结果。当SMARCA4在胃癌中发生突变时，我们的数据表明SMARCA4并不能作为肿瘤抑制因子发挥作用，这可能是由于SWI /SNF异常残留复合物的病理活性所致。</p></sec><sec id="s9"><title>5. 结论</title><p>在这项研究中，通过生物信息学和实验分析，我们发现六个SNP突变基因(TP53，AKT1，HRAS，PTEN，PIK3CA，SMARCA4，BRCA1)可能是胃癌发生发展及预后的关键因素，并且参与了许多与癌症发展有关的信号通路。因此应进行进一步的研究以检测这些基因的多态性位点并探索其相应的表达水平，从而用于预测患者的预后。我们下一步将在大规模临床研究中进行验证，以确定其在肿瘤发生中的准确性和敏感性，并指导患者的个体化精准治疗。本研究的重点是通过生物信息学分析为临床诊断和预后评估提供新的思路，我们的研究结果为指导胃癌的后续研究提供了重要的生物信息学基础和相关的理论基础。</p></sec><sec id="s10"><title>文章引用</title><p>李 晖,吴 昊,马英骥,梁志威,王功竣,齐卫卫,邱文生. 基于生物信息学鉴定和分析SNP突变基因在胃癌中的预后和应用价值Identification and Validation of SNP-Containing Genes with Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis[J]. 临床医学进展, 2020, 10(11): 2832-2847. https://doi.org/10.12677/ACM.2020.1011430</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38953-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ang, T.L. and Fock, K.M. (2014) Clinical Epidemiology of Gastric Cancer. Singapore Medical Journal, 55, 621-628.  
&lt;br&gt;https://doi.org/10.11622/smedj.2014174</mixed-citation></ref><ref id="hanspub.38953-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lazar, D.C., Taban, S., Cornianu, M., Faur, A. and Goldis, A. (2016) New Advances in Targeted Gastric Cancer Treatment. World Journal of Gastroenterology, 22, 6776-6799. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i30.6776</mixed-citation></ref><ref id="hanspub.38953-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Peddanna, N., Holt, S. and Verma, R.S. (1995) Genetics of Gastric Cancer. Anticancer Research, 15, 2055-2064.</mixed-citation></ref><ref id="hanspub.38953-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z. and Hao, K. (2018) Using SAAS-CNV to Detect and Characterize Somatic Copy Number Alterations in Cancer Genomes from Next Generation Sequencing and SNP Array Data. In: Bickhart, D., Ed., Copy Number Variants. Methods in Molecular Biology, Vol. 1833, Humana Press, New York, 29-47.  
&lt;br&gt;https://doi.org/10.1007/978-1-4939-8666-8_2</mixed-citation></ref><ref id="hanspub.38953-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tomczak, K., Czerwinska, P. and Wiznerowicz, M. (2015) The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge. Contemporary Oncology (Pozn), 19, A68-A77. &lt;br&gt;https://doi.org/10.5114/wo.2014.47136</mixed-citation></ref><ref id="hanspub.38953-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Huang da W, Sherman, B.T. and Lempicki, R.A. (2009) Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nature Protocols, 4, 44-57. &lt;br&gt;https://doi.org/10.1038/nprot.2008.211</mixed-citation></ref><ref id="hanspub.38953-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., et al. (2015) STRING v10: Protein-Protein Interaction Networks, Integrated over the Tree of Life. Nucleic Acids Research, 43, D447-D452.  
&lt;br&gt;https://doi.org/10.1093/nar/gku1003</mixed-citation></ref><ref id="hanspub.38953-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. (2003) Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13, 2498-2504.  
&lt;br&gt;https://doi.org/10.1101/gr.1239303</mixed-citation></ref><ref id="hanspub.38953-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chin, C.H., Chen, S.H., Wu, H.H., Ho, C.W., Ko, M.T. and Lin, C.Y. (2014) cytoHubba: Identifying Hub Objects and Sub-Networks from Complex Interactome. BMC Systems Biology, 8, Article No. S11.  
&lt;br&gt;https://doi.org/10.1186/1752-0509-8-S4-S11</mixed-citation></ref><ref id="hanspub.38953-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bader, G.D. and Hogue, C.W. (2003) An Automated Method for Finding Molecular Complexes in Large Protein Interaction Networks. BMC Bioinformatics, 4, Article No. 2. &lt;br&gt;https://doi.org/10.1186/1471-2105-4-2</mixed-citation></ref><ref id="hanspub.38953-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lanczky, A., Nagy, A., Bottai, G., Munkacsy, G., Szabo, A., Santarpia, L., et al. (2016) miRpower: A Web-Tool to Validate Survival-Associated miRNAs Utilizing Expression Data from 2178 Breast Cancer Patients. Breast Cancer Research and Treatment, 160, 439-446. &lt;br&gt;https://doi.org/10.1007/s10549-016-4013-7</mixed-citation></ref><ref id="hanspub.38953-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chandrashekar, D.S., Bashel, B., Balasubramanya, S.A.H., Creighton, C.J., Ponce-Rodriguez, I., Chakravarthi, B., et al. (2017) UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19, 649-658. &lt;br&gt;https://doi.org/10.1016/j.neo.2017.05.002</mixed-citation></ref><ref id="hanspub.38953-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., et al. (2013) Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling, 6, l1.  
&lt;br&gt;https://doi.org/10.1126/scisignal.2004088</mixed-citation></ref><ref id="hanspub.38953-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Li, M., Chen, S., Hu, J., Guo, Q., Liu, R., et al. (2018) Endoscopic Screening in Asian Countries Is Associated with Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review. Gastroenterology, 155, 347- 354 e9. &lt;br&gt;https://doi.org/10.1053/j.gastro.2018.04.026</mixed-citation></ref><ref id="hanspub.38953-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Soussi, T. (2011) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Advances in Cancer Research, 110, 107-139. &lt;br&gt;https://doi.org/10.1016/B978-0-12-386469-7.00005-0</mixed-citation></ref><ref id="hanspub.38953-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, V.D., Li, K.H. and Li, J.T. (2019) TP53 Mutations as Potential Prognostic Markers for Specific Cancers: Analysis of Data from the Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. Journal of Cancer Research and Clinical Oncology, 145, 625-636. &lt;br&gt;https://doi.org/10.1007/s00432-018-2817-z</mixed-citation></ref><ref id="hanspub.38953-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wang, M., Yang, C., Zhang, X. and Li, X. (2018) Characterizing Genomic Differences of Human Cancer Stratified by the TP53 Mutation Status. Molecular Genetics and Genomics, 293, 737-746.  
&lt;br&gt;https://doi.org/10.1007/s00438-018-1416-7</mixed-citation></ref><ref id="hanspub.38953-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ando, K., Oki, E., Zhao, Y., Ikawa-Yoshida, A., Kitao, H., Saeki, H., et al. (2014) Mortalin Is a Prognostic Factor of Gastric Cancer with Normal p53 Function. Gastric Cancer, 17, 255-262. &lt;br&gt;https://doi.org/10.1007/s10120-013-0279-1</mixed-citation></ref><ref id="hanspub.38953-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Uchi, R., Kogo, R., Kawahara, K., Sudo, T., Yokobori, T., Eguchi, H., et al. (2013) PICT1 Regulates TP53 via RPL11 and Is Involved in Gastric Cancer Progression. British Journal of Cancer, 109, 2199-2206.  
&lt;br&gt;https://doi.org/10.1038/bjc.2013.561</mixed-citation></ref><ref id="hanspub.38953-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Y., Wu, Z., Guo, W. and Li, J. (2015) Gene Mutations in Gastric Cancer: A Review of Recent Next-Generation Sequencing Studies. Tumor Biology, 36, 7385-7394. &lt;br&gt;https://doi.org/10.1007/s13277-015-4002-1</mixed-citation></ref><ref id="hanspub.38953-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Z., Liu, Z., Li, M., Chen, C. and Wang, X. (2018) Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. Translational Oncology, 11, 1171-1187.  
&lt;br&gt;https://doi.org/10.1016/j.tranon.2018.07.012</mixed-citation></ref><ref id="hanspub.38953-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., Balmain, A. and Counter, C.M. (2018) A Model for RAS Mutation Patterns in Cancers: Finding the Sweet Spot. Nature Reviews Cancer, 18, 767-777. &lt;br&gt;https://doi.org/10.1038/s41568-018-0076-6</mixed-citation></ref><ref id="hanspub.38953-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S., Li, F., Xu, D., Hou, K., Fang, W. and Li, Y. (2019) The Function of RAS Mutation in Cancer and Advances in its Drug Research. Current Pharmaceutical Design, 25, 1105-1114.  
&lt;br&gt;https://doi.org/10.2174/1381612825666190506122228</mixed-citation></ref><ref id="hanspub.38953-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Geyer, F.C., Li, A., Papanastasiou, A.D., Smith, A., Selenica, P., Burke, K.A., et al. (2018) Recurrent Hotspot Mutations in HRAS Q61 and PI3K-AKT Pathway Genes as Drivers of Breast Adenomyoepitheliomas. Nature Communications, 9, 1816. &lt;br&gt;https://doi.org/10.1038/s41467-018-04128-5</mixed-citation></ref><ref id="hanspub.38953-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Pecenka, V., Pajer, P., Karafiat, V., Kasparova, P., Dudlova, J. and Dvorak, M. (2017) HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2. Journal of Virology, 91(20). &lt;br&gt;https://doi.org/10.1128/JVI.00467-17</mixed-citation></ref><ref id="hanspub.38953-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X. and Zhang, Y. (2015) Bladder Cancer and Genetic Mutations. Cell Biochemistry and Biophysics, 73, 65-69.  
&lt;br&gt;https://doi.org/10.1007/s12013-015-0574-z</mixed-citation></ref><ref id="hanspub.38953-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Untch, B.R., Dos Anjos, V., Garcia-Rendueles, M.E.R., Knauf, J.A., Krishnamoorthy, G.P., Saqcena, M., et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 78, 4642-4657.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-17-1925</mixed-citation></ref><ref id="hanspub.38953-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wu, X.Y., Liu, W.T., Wu, Z.F., Chen, C., Liu, J.Y., Wu, G.N., et al. (2016) Identification of HRAS as Cancer-Pro- moting Gene in Gastric Carcinoma Cell Aggressiveness. American Journal of Cancer Research, 6, 1935-1948.</mixed-citation></ref><ref id="hanspub.38953-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Jhanwar-Uniyal, M. (2003) BRCA1 in Cancer, Cell Cycle and Genomic Stability. Frontiers in Bioscience, 8, s1107- s1117. &lt;br&gt;https://doi.org/10.2741/1131</mixed-citation></ref><ref id="hanspub.38953-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Somasundaram, K. (2003) Breast Cancer Gene 1 (BRCA1): Role in Cell Cycle Regulation and DNA Repair—Perhaps through Transcription. Journal of Cellular Biochemistry, 88, 1084-1091.</mixed-citation></ref><ref id="hanspub.38953-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Paul, A. and Paul, S. (2014) The Breast Cancer Susceptibility Genes (BRCA) in Breast and Ovarian Cancers. Frontiers in Bioscience (Landmark Ed), 19, 605-618.</mixed-citation></ref><ref id="hanspub.38953-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Oh, M., McBride, A., Yun, S., Bhattacharjee, S., Slack, M., Martin, J.R., et al. (2018) BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 110, 1178-1189. &lt;br&gt;https://doi.org/10.1093/jnci/djy148</mixed-citation></ref><ref id="hanspub.38953-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Wang, G.H., Zhao, C.M., Huang, Y., Wang, W., Zhang, S. and Wang, X. (2018) BRCA1 and BRCA2 Expression Patterns and Prognostic Significance in Digestive System Cancers. Human Pathology, 71, 135-144.  
&lt;br&gt;https://doi.org/10.1016/j.humpath.2017.10.032</mixed-citation></ref><ref id="hanspub.38953-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X.R., Zhang, W.Z., Lin, X.Q. and Wang, J.W. (2006) Genetic Instability of BRCA1 Gene at Locus D17S855 Is Related to Clinicopathological Behaviors of Gastric Cancer from Chinese Population. World Journal of Gastroenterology, 12, 4246-4249. &lt;br&gt;https://doi.org/10.3748/wjg.v12.i26.4246</mixed-citation></ref><ref id="hanspub.38953-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Shim, H.J., Yun, J.Y., Hwang, J.E., Bae, W.K., Cho, S.H., Lee, J.H., et al. (2010) BRCA1 and XRCC1 Polymorphisms Associated with Survival in Advanced Gastric Cancer Treated with Taxane and Cisplatin. Cancer Science, 101, 1247- 1254. &lt;br&gt;https://doi.org/10.1111/j.1349-7006.2010.01514.x</mixed-citation></ref><ref id="hanspub.38953-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S. and Baradaran, B. (2019) The Relation between PI3K/AKT Signalling Pathway and Cancer. Gene, 698, 120-128. &lt;br&gt;https://doi.org/10.1016/j.gene.2019.02.076</mixed-citation></ref><ref id="hanspub.38953-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Mayer, I.A. and Arteaga, C.L. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 67, 11-28. &lt;br&gt;https://doi.org/10.1146/annurev-med-062913-051343</mixed-citation></ref><ref id="hanspub.38953-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Xu, Y., Zhou, Q., Chen, M., Zhang, Y., Liang, H., et al. (2018) PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment. Future Oncology, 14, 665-674. &lt;br&gt;https://doi.org/10.2217/fon-2017-0588</mixed-citation></ref><ref id="hanspub.38953-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Sobral-Leite, M., Salomon, I., Opdam, M., Kruger, D.T., Beelen, K.J., van der Noort, V., et al. (2019) Cancer-Immune Interactions in ER-Positive Breast Cancers: PI3K Pathway Alterations and Tumor-Infiltrating Lymphocytes. Breast Cancer Research, 21, Article No. 90. &lt;br&gt;https://doi.org/10.1186/s13058-019-1176-2</mixed-citation></ref><ref id="hanspub.38953-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Stachler, M.D., Rinehart, E.M., Garcia, E. and Lindeman, N.I. (2016) PIK3CA Mutations Are Common in Many Tumor Types and Are Often Associated with Other Driver Mutations. Applied Immunohistochemistry &amp; Molecular Morphology, 24, 313-319. &lt;br&gt;https://doi.org/10.1097/PAI.0000000000000195</mixed-citation></ref><ref id="hanspub.38953-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Alvarez-Cubero, M.J., Martinez-Gonzalez, L.J., Robles-Fernandez, I., Martinez-Herrera, J., Garcia-Rodriguez, G., Pascual-Geler, M., et al. (2017) Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. Molecular Diagnosis &amp; Therapy, 21, 167-178. &lt;br&gt;https://doi.org/10.1007/s40291-016-0248-6</mixed-citation></ref><ref id="hanspub.38953-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Huang, D., Sun, W., Zhou, Y., Li, P., Chen, F., Chen, H., et al. (2018) Mutations of Key Driver Genes in Colorectal Cancer Progression and Metastasis. Cancer and Metastasis Reviews, 37, 173-187.  
&lt;br&gt;https://doi.org/10.1007/s10555-017-9726-5</mixed-citation></ref><ref id="hanspub.38953-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Liu, S., Tang, Y., Yan, M. and Jiang, W. (2018) PIK3CA Mutation Sensitizes Breast Cancer Cells to Synergistic Therapy of PI3K Inhibition and AMPK Activation. Investigational New Drugs, 36, 763-772.  
&lt;br&gt;https://doi.org/10.1007/s10637-018-0563-3</mixed-citation></ref><ref id="hanspub.38953-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H. and Zhou, L. (2019) Single Nucleotide Polymorphism of PIK3CA and Its Interaction with the Environment Are Risk Factors for Chinese Han Ovarian Cancer. Pathology—Research and Practice, 215, 152520.  
&lt;br&gt;https://doi.org/10.1016/j.prp.2019.152520</mixed-citation></ref><ref id="hanspub.38953-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Jang, S.H., Kim, K.J., Oh, M.H., Lee, J.H., Lee, H.J., Cho, H.D., et al. (2016) Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. Journal of Gastric Cancer, 16, 85-92.  
&lt;br&gt;https://doi.org/10.5230/jgc.2016.16.2.85</mixed-citation></ref><ref id="hanspub.38953-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Polom, K., Marrelli, D., Roviello, G., Pascale, V., Voglino, C., Vindigni, C., et al. (2018) PIK3CA Mutation in Gastric Cancer and the Role of Microsatellite Instability Status in Mutations of Exons 9 and 20 of the PIK3CA Gene. Advances in Clinical and Experimental Medicine, 27, 963-969.</mixed-citation></ref><ref id="hanspub.38953-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Shen, X., Zhao, Y., Chen, X., Sun, H., Liu, M., Zhang, W., et al. (2019) Associations of PIK3CA Mutations with Clinical Features and Prognosis in Gastric Cancer. Future Oncology, 15, 1873-1894. &lt;br&gt;https://doi.org/10.2217/fon-2018-0335</mixed-citation></ref><ref id="hanspub.38953-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Song, M., Bode, A.M., Dong, Z. and Lee, M.H. (2019) AKT as a Therapeutic Target for Cancer. Cancer Research, 79, 1019-1031. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-18-2738</mixed-citation></ref><ref id="hanspub.38953-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">LoPiccolo, J., Granville, C.A., Gills, J.J. and Dennis, P.A. (2007) Targeting Akt in Cancer Therapy. Anticancer Drugs, 18, 861-874.</mixed-citation></ref><ref id="hanspub.38953-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Petrini, I., Lencioni, M., Vasile, E., Fornaro, L., Belluomini, L., Pasquini, G., et al. (2018) EGFR and AKT1 Overexpression Are Mutually Exclusive and Associated with a Poor Survival in Resected Gastric Adenocarcinomas. Cancer Biomarkers, 21, 731-741. &lt;br&gt;https://doi.org/10.3233/CBM-170865</mixed-citation></ref><ref id="hanspub.38953-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Ghatak, S., Lalnunhlimi, S., Lalrohlui, F., Pautu, J.L., Zohmingthanga, J., Kunnumakkara, A.B., et al. (2018) Novel AKT1 Mutations Associated with Cell-Cycle Abnormalities in Gastric Carcinoma. Personalized Medicine, 15, 79-86.  
&lt;br&gt;https://doi.org/10.2217/pme-2017-0053</mixed-citation></ref><ref id="hanspub.38953-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Hargreaves, D.C. and Crabtree, G.R. (2011) ATP-Dependent Chromatin Remodeling: Genetics, Genomics and Mechanisms. Cell Research, 21, 396-420. &lt;br&gt;https://doi.org/10.1038/cr.2011.32</mixed-citation></ref><ref id="hanspub.38953-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Khavari, P.A., Peterson, C.L., Tamkun, J.W., Mendel, D.B. and Crabtree, G.R. (1993) BRG1 Contains a Conserved Domain of the SWI2/SNF2 Family Necessary for Normal Mitotic Growth and Transcription. Nature, 366, 170-174.  
&lt;br&gt;https://doi.org/10.1038/366170a0</mixed-citation></ref><ref id="hanspub.38953-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Glaros, S., Cirrincione, G.M., Palanca, A., Metzger, D. and Reisman, D. (2008) Targeted Knockout of BRG1 Potentiates Lung Cancer Development. Cancer Research, 68, 3689-3696. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-07-6652</mixed-citation></ref><ref id="hanspub.38953-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Buscarlet, M., Krasteva, V., Ho, L., Simon, C., Hebert, J., Wilhelm, B., et al. (2014) Essential Role of BRG, the ATPase Subunit of BAF Chromatin Remodeling Complexes, in Leukemia Maintenance. Blood, 123, 1720-1728.  
&lt;br&gt;https://doi.org/10.1182/blood-2013-02-483495</mixed-citation></ref><ref id="hanspub.38953-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Q., Madany, P., Akech, J., Dobson, J.R., Douthwright, S., Browne, G., et al. (2015) The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 230, 2683-2694.</mixed-citation></ref><ref id="hanspub.38953-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Laurette, P., Coassolo, S., Davidson, G., Michel, I., Gambi, G., Yao, W., et al. (2020) Chromatin Remodellers Brg1 and Bptf Are Required for Normal Gene Expression and Progression of Oncogenic Braf-Driven Mouse Melanoma. Cell Death &amp; Differentiation, 27, 29-43. &lt;br&gt;https://doi.org/10.1038/s41418-019-0333-6</mixed-citation></ref></ref-list></back></article>